Abstract：
As the characteristics of preterm infants with retinopathy of prematurity (ROP) vary, depending on the quality of neonatal care they received, universal screening criteria for ROP are not possible. The purpose of this study was to compare ROP guidelines for those planning to develop guidelines, particularly in resource-poor settings.A systematic review was undertaken of PubMed, Embase and guidelines registers to identify national or international policy statements or guidelines in English, issued or operational in 2010-2021. Bibliographies of two publications were also reviewed. The searches identified 633, 1081 and 317 records, respectively, and 157 records were retrieved from other sources. 23 publications were included in the analysis.Most included documents defined cut-offs for screening as <32 weeks gestational age (GA) or ≤1500g birth weight (BW). The highest values were in the Philippines (<35 weeks GA; <2000g) and India (≤34 weeks GA; <2000g). The lowest were in high-income countries, i.e. the United States of America (≤32 weeks for GA) and New Zealand (<1250g for BW). Most guidelines included additional risk factors to consider. The most frequent indication for when screening should start was a combination of GA and chronological age. All but one document defined when screening could stop. There was general consensus on the indications, timing and methods of treatment. Indications for anti-VEGF therapy varied between countries.Guidelines were identified for a limited number of countries with none from low-income settings. Variation in the indications for screening reflects the varying exposure to risk factors in different settings.
摘要：
由于早产儿视网膜病变(ROP)的特点各异,取决于他们接受的新生儿护理的质量，ROP的通用筛选标准是不可能的。这项研究的目的是比较那些计划制定指南的ROP指南，特别是在资源贫乏的环境中。对PubMed进行了系统审查，Embase和准则登记册，以确定国家或国际政策声明或英文准则，2010-2021年发行或运营。还审查了两个出版物的参考书目。搜索确定了633、1081和317条记录，分别,并从其他来源检索了157条记录。分析中包括23种出版物。大多数文件包括定义为<32周胎龄（GA）或≤1500g出生体重（BW）的筛选截止值。最高值在菲律宾（<35周GA；<2000g）和印度（≤34周GA；<2000g）。最低的是高收入国家，即美利坚合众国（GA≤32周）和新西兰（BW<1250g）。大多数指南包括需要考虑的其他风险因素。筛查何时开始的最常见指标是GA和实际年龄的组合。除一个文件外，所有文件都定义了筛选可以停止的时间。就这些迹象达成了普遍共识，治疗的时机和方法。不同国家抗VEGF治疗的适应症各不相同。为少数低收入国家确定了准则。筛查适应症的变化反映了不同环境下对风险因素的不同暴露。
